Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications

ConclusionsLXB monotherapy was effective in reducing cataplexy and increasing cataplexy-free days. These results illustrate the feasibility of switching from SXB to LXB while tapering/discontinuing other anticataplectics.Trial RegistrationA Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy;https://clinicaltrials.gov/ct2/show/NCT03030599; clinicaltrials.gov identifier: NCT03030599.
Source: CNS Drugs - Category: Neurology Source Type: research